Tamoxifen retains cancer-preventive efficacy with concomitant hormonal contraceptive in a rat mammary tumorigenesis model
Abstract Whether hormonal contraceptives (HCs) impair tamoxifen efficacy in premenopausal women is unknown. Using a rat estrogen receptor-positive mammary tumorigenesis model, we found that combined HC (17α-ethinylestradiol + levonorgestrel) did not reduce the cancer-preventive tamoxifen efficacy. No cancers occurred with tamoxifen + HC treatment, 16.7% in tamoxifen-alone and 91.7% in controls (p < 0.001). Tamoxifen-associated reproductive adverse events were not increased by HC co-administration. HC use by premenopausal women taking tamoxifen merits clinical evaluation.
Authors
- Oukseub Lee (ORCID: https://orcid.org/0000-0003-0279-5460)
- Maarten C. Bosland (ORCID: https://orcid.org/0000-0002-0023-6975)
- Seema Khan
- Alexander Eremin
Institutions
- Northwestern University (US)
- University of Illinois Chicago (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-17
- DOI
- https://doi.org/10.21203/rs.3.rs-10809706/v1
- Primary Topic
- Estrogen and related hormone effects
- Type
- preprint